Hanover - Delayed Quote EUR

Illumina Inc (ILU.HA)

67.68

-0.48

(-0.70%)

At close: April 25 at 5:25:19 PM GMT+2

Should You Hold Illumina (ILMN)?

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. 2025 got out to a solid start with the market hitting all-time highs in mid-February. However, a dramatic reversal pushed the S&P 500 down 8.7%, closing the […]

Insider Monkey yesterday

ILMN
This Cancer Test Could Become Routine—and a Big Seller, Says Analyst

Grail cutting-edge cancer blood test has stirred investor excitement many times in the past few years. With the stock down 55% from its February peak, Canaccord Genuity issued a Buy recommendation on Monday. Grail hopes its multicancer blood test will eventually become part of routine checkups.

Barrons.com 4 days ago

ILMN

GRAL
Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns

We recently published a list of 15 Recent Activist Investor Campaigns. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against other recent activist investor campaigns. Economic uncertainty and market volatility are some of the factors fueling activist investor campaigns in 2025. In the first quarter alone, there […]

Insider Monkey 4 days ago

ILMN
Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Illumina (NASDAQ:ILMN) and the rest of the life sciences tools & services stocks fared in Q4.

StockStory 7 days ago

ILMN

TECH
Illumina, Tempus AI partner to drive genomic testing beyond cancer

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.

MedTech Dive 7 days ago

TEM

ILMN
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular tes

PR Newswire 10 days ago

ILMN

TEM
1 Healthcare Stock for Long-Term Investors and 2 to Keep Off Your Radar

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 14.1%. This performance was worse than the S&P 500’s 9.3% decline.

StockStory 14 days ago

ADUS

ILMN
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025.

PR Newswire 15 days ago

ILMN
Here's Why Illumina (ILMN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 21 days ago

ILMN
Argus cuts Illumina target, sees buying opportunity

Argus lowered the firm’s price target on Illumina (ILMN) to $100 from $170 and keeps a Buy rating on the shares. The stock has fallen significantly over the past several months amid geopolitical tensions, antitrust issues, and slowing product sales, the analyst tells investors in a research note. However, the firm believes Illumina “appears to be turning the corner,” delivering multiple quarters of margin growth, launching new products and services, and providing “strong” earnings guidance for 2

TipRanks 24 days ago

ILMN
3 Mid-Cap Stocks Walking a Fine Line

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

StockStory 24 days ago

KMX

DVA

ILMN
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain

Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.

Investor's Business Daily 29 days ago

BSX

ISRG

JNJ
Cintas, UPS, Illumina: Market Minute

Here are some of the stocks on the move on Tuesday, March 25. Cintas (CTAS) has ended discussions about acquiring UniFirst (UNF). Shares of UPS (UPS) are slipping following a Bank of America note warning about its first quarter earnings. Illumina (ILMN) is adding some new faces to its board of directors. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video last month

CTAS

ILMN

UPS
Activist Investor Meister to Join Illumina’s Board

Activist investor Keith Meister will join the board of directors of troubled gene-sequencing maker Illumina and current board member Scott Gottlieb will become chairman. The moves, which the company announced Tuesday after The Wall Street Journal reported they were coming, will take effect Friday. Meister’s hedge fund, Corvex Management, first invested in Illumina in 2023 and has a stake of about 2.5% of the company’s shares, people familiar with the matter said.

The Wall Street Journal last month

ILMN
Illumina shares rise on WSJ report activist investor Meister will join board

Investing.com -- Illumina shares rose over 2% premarket on Tuesday, following a Wall Street Journal report that activist investor Keith Meister would join the company’s board of directors.

Investing.com last month

ILMN
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Holo

PR Newswire last month

ILMN
Activist investor Keith Meister to join Illumina's board

Illumina said on Tuesday activist investor Keith Meister would join the gene-sequencing maker's board and former U.S. Food and Drug Administration Commissioner Scott Gottlieb would take over as the company's chairman later this week. Illumina has been caught in the middle of a tariff war between the U.S. and China that has compelled it to cut its annual forecast and implement a cost-savings plan. China, which accounts for 7% of Illumina's sales, has banned imports of the company's genetic sequencers in response to U.S. President Donald Trump's additional 10% tariff on Chinese goods.

Reuters last month

ILMN
Is Illumina, Inc. (ILMN) the Best Diagnostics Stock to Invest in Right Now?

We recently published a list of the 12 Best Diagnostics Stocks to Invest In Right Now. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against the other best diagnostics stocks to invest in right now. Overview of the Clinical Diagnostics Market According to a report by Mordor […]

Insider Monkey last month

ILMN
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?

ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.

Zacks last month

ILMN

BSX
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery

Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic research and clinical development.

PR Newswire last month

ILMN

Performance Overview

Return	ILU.HA	S&P 500 (^GSPC)
YTD	-47.39%	-6.06%
1-Year	-40.46%	+9.44%
3-Year	-78.03%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Illumina Inc (ILU.HA)

Should You Hold Illumina (ILMN)?

This Cancer Test Could Become Routine—and a Big Seller, Says Analyst

Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns

Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks

Illumina, Tempus AI partner to drive genomic testing beyond cancer

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

1 Healthcare Stock for Long-Term Investors and 2 to Keep Off Your Radar

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

Here's Why Illumina (ILMN) is a Strong Value Stock

Argus cuts Illumina target, sees buying opportunity

3 Mid-Cap Stocks Walking a Fine Line

How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain

Cintas, UPS, Illumina: Market Minute

Activist Investor Meister to Join Illumina’s Board

Illumina shares rise on WSJ report activist investor Meister will join board

Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

Activist investor Keith Meister to join Illumina's board

Is Illumina, Inc. (ILMN) the Best Diagnostics Stock to Invest in Right Now?

Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?

Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery

Performance Overview